SLC5A2 and hypertrophic cardiomyopathy: Additional arguments in furtherance of an impaired cardiac glucose metabolism were provided by demonstrating that treatment with the hypoglycemic sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin prevented the development of hypertrophic cardiomyopathy inBSCL2–/– mice.